Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Chooses mRNA Boosters For COVID-19 Vaccination Campaign

Executive Summary

In making its recommendations for the autumn vaccination program against COVID-19, the UK’s JCVI says Novavax’s Nuvaxovid could be used in exceptional circumstances, but there is no room for AstraZeneca’s Vaxzevria.

You may also be interested in...



UK First To Approve Moderna’s Bivalent COVID-19 Vaccine

The mRNA-1273.214 vaccine will add to the UK’s armory for protecting people against coronavirus over the coming winter season.

Pfizer/BioNTech Bolster Case For Omicron Vaccines

The bivalent vaccine is likely to get regulatory support, along with government contracts, but competitors, notably Moderna, will also step into the ring.

EU To Kick Off ‘Joint Action’ On Tackling Drug Shortages

The joint action on ensuring security of medicines supply will be supported by the EU regulators’ shortages task force, which is to track efforts to coordinate member state activities on the supply and availability of medicines.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel